Clinical Trial Update: Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the safety and potential efficacy of adding a short course of a MEK inhibitor to chemoimmunotherapy as first-line treat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• MEK inhibitor (unspecified) (MEK inhibitor)

Snippet

Sponsor: Centre Georges Francois Leclerc | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING